AN INTEGRAL COMPONENT OF THE TREATMENT OF PAIN AND INFLAMMATION IN THE ORAL CAVITY IN 60 COUNTRIES WORLDWIDE!2

- JAWS FRACTURES3
- IMPLANTS PLACEMENT4
- WOUNDS OF ORAL CAVITY5

LOCAL ANESTHETIC AND ANTI-INFLAMMATORY EFFECT1

SUMMARY OF PRODUCT CHARACTERISTICS
NAME OF THE MEDICINAL PRODUCT. Tantum Verde 0.15% mouthwash, QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 100 ml contains: active ingredient: benzylamine hydrochloride 0.15 g (equivalent to 0.134 g of benzylamine). Therapeutic indications. Treatment of symptoms such as inflammation/inflammation including those associated with pain in the oropharyngeal cavity (e.g., gingival, stomatitis and pharyngitis), including those resulting from conservative or extracting dental therapy. Dosage and method of administration. Pour 15 ml of Tantum Verde mouthwash into the measuring cup. 1-3 times per day, using 6 checker of 1/4 concentration or diluted. If desired, add 15 ml of water to the graduated cup. Do not exceed the recommended dosage. Contraindications. Hypersensitivity to benzylamine or to any of the excipients. PHARMACOLOGICAL PROPERTIES. Pharmacodynamic properties. Pharmacotherapeutic group: Systemic Avonishipic Drug: other agents for local oral treatment. ATC code: AI01 AL03. Clinical studies demonstrated that benzylamine is effective in relieving symptoms from local irritations of the mouth and pharynx. In addition, benzylamine possesses a moderate local anesthetic effect. Pharmacokinetic properties. Absorption. Absorption through the oropharyngeal mucosa is demonstrated by the presence of measurable quantities of benzylamine in human plasma. These levels are insufficient to produce systemic effects. Distribution. When applied locally, benzylamine has been shown to accumulate in inflamed tissues where it reaches effective concentrations because of its capacity to penetrate the epithelial lining. Information about medicines. Information for health care professionals for use in professional activities.
1. Инструкция для медицинского применения анестезирующего засола Тантум Вerde®, действенный дляdoğanской регистрации, ПТФ № UA/39200/01/01, зарегистрирован в Министерстве здравоохранения России, № 04119, Киев, Мельникова 83/3, оф. 404.
Official Title

*Journal of Diagnostics and Treatment of Oral and Maxillofacial Pathology*

**Standard Abbreviation:** ISO 4


**Acronym**

*JDTOMP*

**International Standard Serial Number (ISSN)**

Electronic ISSN 2522-1965

**Aims & Scope**

This is a monthly peer-reviewed oral and maxillofacial surgery journal focused on: microvascular and jaw reconstructive surgery, dental implants, salivary gland tumors/diseases, TMJ lesions, virtual surgical planning, implementation of ultrasonography into the practice of oral and maxillofacial surgeons.

**Editorial Board (EB) Composition**

- EB shows significant geographic diversity representing 30 opinion leaders from 13 countries: Brazil, Canada, Colombia, Greece, Hong Kong (SAR, China), India, Israel, Italy, Slovak Republic, Spain, Ukraine, United Arab Emirates, and United States.
- The majority of the EB Members have a discernible publication history in Scopus, Web of Science, and journals with a high impact factor.
- The publication records of all EB members are consistent with the stated scope and published content of the journal.
- The journal has a several full-time professional editors.
- Gender distribution of the editors: 10% women, 90% men, 0% non-binary/other, and 0% prefer not to disclose.

**Frequency**

12 issues a year (from January 2020)

**Publication History**

2017: 4 issues a year
2018: 4 issues a year
2019: 10 issues a year
From 2020: 12 issues a year

**Publishing Model**

*Journal of Diagnostics and Treatment of Oral and Maxillofacial Pathology* is a fully online-only open access and peer-reviewed publication.

**Type of Peer Review**

The journal employs “double blind” reviewing.

**Article Publishing Charge (APC)**

The APC in this journal is US $500 and US $250 (excluding taxes) depending on the article’s type. Details at website: dtjournal.org.

**13 Types of Articles Currently Published by the Journal**

Editortials/Guest Editorials/Post Scriptum Editorials, Images, Case Reports/Case Series, Original Articles, Review Articles, Discussions, Paper Scans (synonym: Review of Articles, Literature Scan), Book Scans (synonym: Book Reviews), Letters to the Editor (synonym: Letters), and Viewpoints.

**State Registration: Ministry of Justice of Ukraine**

Registration: Jul 28, 2016 (Certificate: КВ № 22251-12151 Р)
Re-registration: May 21, 2019 (Certificate: КВ № 23999-13839 ПР)
Re-registration: Aug 10, 2021 (Certificate: КВ № 24951-14891 ПР)

**Co-Founders**

1. Shupyk National Healthcare University of Ukraine (formerly known as Shupyk National Medical Academy of Postgraduate Education).
2. Private Higher Educational Establishment “Kyiv Medical University.”

**Publisher**

OMF Publishing, LLC is an academic publisher focused on medical and linguistic sciences.
Address: 13-A Simferopolska Street, office 121, Kyiv 02096, Ukraine.

**Crossref Membership**

OMF Publishing, LLC is a member of Publishers International Linking Association, Inc. which doing business as a Crossref. OMF Publishing’s active membership: From February 2017 to present.

**Official Journal of the Association**

Ukrainian Association for Maxillofacial and Oral Surgeons

**Ukrainian Association for Maxillofacial and Oral Surgeons (UAMOS)**

Address: 4-A Profesora Pidvysotskoho Street, Kyiv 01103, Ukraine.
Tel., fax: +38 044 528 35 17.
Website: uamos.org.

© 2022 OMF PUBLISHING, LLC
Editorial Board

Editor in Chief
Oleksii O. Tymofieiev, ScD
Kyiv, Ukraine

Deputy Editor in Chief
Rui P. Fernandes, MD, DMD, FACS, FRCS(Ed)
Jacksonville, Florida, United States

Section Editors

Bone Augmentation Techniques
Nardy Casap, MD, DMD
Jerusalem, Israel

Head & Neck Oncologic Surgery
Todd C. Hanna, MD, DDS, FACS
New York, New York, United States

Business
Ivan V. Nagorniak, MSc, PhD
Kyiv, Ukraine

Head & Neck Radiology
Anil T. Ahuja, MBBS, MD, FRCR, FHKCR, FHKAM
Hong Kong, SAR, China

Craniofacial Deformities
Sunil Richardson, MDS
Nagercoil, Tamil Nadu, India

Images
Camilo Mosquera, DDS
Bogotá, D.C., Colombia

Facial Feminization Surgery
Kyle Keojampa, MD, FACS
Los Angeles, California, United States

Orthognathic Surgery
Mario Brinhole
São Paulo, São Paulo, Brazil

Facial Plastic Surgery
Tirbod Fattahi, MD, DDS, FACS
Jacksonville, Florida, United States

Robotic Surgery
Salam O. Salman, MD, DDS, FACS
Jacksonville, Florida, United States

TMJ Lesions/Disorders
Belmiro C. Vasconcelos, DDS, PhD
Recife, Pernambuco, Brazil

Editorial Board Members

Oleh M. Antonyshyn, MD, FRCS(C)
Toronto, Ontario, Canada

Anastasiya Quimby, DDS, MD
Fort Lauderdale, Florida, United States

Anthony M. Bunnell, MD, DMD, FACS
Jacksonville, Florida, United States

Daniel Robles Cantero, DDS, MSc
Madrid, Spain

Nur A. Hatab, DMD, PhD
Ras Al Khaimah, United Arab Emirates

Peter Stanko, MD, PhD
Bratislava, Slovak Republic

Michael T. Kase, DMD
Birmingham, Alabama, United States

Rostyslav M. Stupnytskyi, ScD
Kyiv, Ukraine

Andrey V. Kopchak, ScD
Kyiv, Ukraine

Olexander O. Tymofieiev, ScD
Kyiv, Ukraine

Olindo Massarelli, MD, PhD, FEBOMFS
Sassari, Italy

Andrew Yanpolsky, DDS, MD
Philadelphia, Pennsylvania, United States

Web & Social Media Editor
João L. Monteiro, DDS
Boston, Massachusetts, United States

Managing Editor
Ievgen I. Fesenko, PhD
Kyiv, Ukraine

Director, Journal Development Department
Evangelos G. Kilipiris, DMD
Thessaloniki, Greece | Bratislava, Slovak Republic

Resident Ambassador
John M. Le, DDS, MD
Birmingham, Alabama, United States
**Composition:**

active substance: benzydamine hydrochloride;
100 mL of solution contain benzydamine hydrochloride 0.15 g;
excipients: ethanol 96%, glycerol, methyl parahydroxybenzoate (E 218), flavor (menthol), saccharin, sodium hydrocarbonate, Polysorbate 20, Quinoline Yellow (E 104), Patent Blue V (E 131), purified water.

**Dosage form.** Oromucosal solution.

Basic physical and chemical properties: a clear green liquid with a typical mint flavor.

**Pharmacotherapeutic group.** Dental preparations. Other agents for local oral treatment.

ATC code: A01A D02.

**Pharmacological properties.**

Pharmacodynamics.

Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antiexudative properties.

Clinical studies have shown that benzydamine is effective in the relief of symptoms accompanying localized irritation conditions of the oral cavity and pharynx. Moreover, benzydamine has anti-inflammatory and local analgesic properties, and also exerts a local anesthetic effect on the oral mucosa.

Pharmacokinetics.

Absorption through the oral and pharyngeal mucosa has been proven by the presence of measurable quantities of benzydamine in human plasma. However, they are insufficient to produce any systemic pharmacological effect. The excretion occurs mainly in urine, mostly as inactive metabolites or conjugated compounds.

When applied locally, benzydamine has been shown to cumulate in inflamed tissues in an effective concentration due to its ability to permeate through the mucous membrane.

**Clinical particulars.**

**Indications.**

Symptomatic treatment of oropharyngeal irritation and inflammation; to relieve pain caused by gingivitis, stomatitis, pharyngitis; in dentistry after tooth extraction or as a preventive measure.

**Contraindications.**

Hypersensitivity to the active substance or to any other ingredients of the product.

**Interaction with other medicinal products and other types of interaction.**

No drug interaction studies have been performed.

**Warnings and precautions.**

If sensitivity develops with long-term use, the treatment should be discontinued and a doctor should be consulted to get appropriate treatment.

In some patients, buccal/pharyngeal ulceration may be caused by severe pathological processes. Therefore, the patients, whose symptoms worsen or do not improve within 3 days or who appear feverish or develop other symptoms, should seek advice of a physician or a dentist, as appropriate.

Benzydamine is not recommended for use in patients hypersensitive to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).

The product can trigger bronchospasm in patients suffering from or with a history of asthma. Such patients should be warned of this.

For athletes: the use of medicinal products containing ethyl alcohol might result in positive antidoping tests considering the limits established by some sports federations.
Use during pregnancy or breast-feeding

No adequate data are currently available on the use of benzydamine in pregnant and breastfeeding women. Excretion of the product into breast milk has not been studied. The findings of animal studies are insufficient to make any conclusions about the effects of this product during pregnancy and lactation.

The potential risk for humans is unknown.

TANTUM VERDE should not be used during pregnancy or breast-feeding.

Effects on reaction time when driving or using machines

When used in recommended doses, the product does not produce any effect on the ability to drive and operate machinery.

Method of administration and doses.

Pour 15 mL of TANTUM VERDE solution from the bottle into the measuring cup and gargle with undiluted or diluted product (15 mL of the measured solution can be diluted with 15 mL of water). Gargle 2 or 3 times daily. Do not exceed the recommended dose.

Children.

The product should not be used in children under 12 years due to a possibility of ingestion of the solution when gargling.

Overdosage.

No overdose has been reported with benzydamine when used locally. However, it is known that benzydamine, when ingested in high doses (hundreds times higher than those possible with this dosage form), especially in children, can cause agitation, convulsions, tremor, nausea, increased sweating, ataxia, and vomiting. Such acute overdose requires immediate gastric lavage, treatment of fluid/salt imbalance, symptomatic treatment, and adequate hydration.

Adverse reactions.

Within each frequency group, the undesirable effects are presented in order of their decreasing seriousness.

Adverse reactions are classified according to their frequency: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1000 to <1/1000); rare (≥ 1/10,000 to <1/1000); very rare (<1/10,000); frequency unknown (cannot be estimated from the available data).

Gastrointestinal disorders: rare – burning mouth, dry mouth; unknown – oral hypesthesia, nausea, vomiting, tongue edema and discoloration, dysgeusia.

Immune system disorders: rare – hypersensitivity reaction, unknown - anaphylactic reaction.

Respiratory, thoracic and mediastinal disorders: very rare –laryngospasm; unknown – bronchospasm.

Skin and subcutaneous tissue disorders: uncommon – photosensitivity; very rare – angioedema; unknown – rash, pruritus, urticaria.

Nervous system disorders: unknown – dizziness, headache.

TANTUM VERDE contains methyl parahydroxybenzoate, which can cause allergic reactions (including delayed-type reactions).

Shelf life. 4 years.

Storage conditions.

Do not store above 25°C. Keep out of reach of children.

Packaging.

120 mL of solution in a bottle with a measuring cup; 1 bottle per cardboard box.

Dispensing category.

Over-the-counter medicinal product.

Manufacturer.


Location of the manufacturer and its business address.

Via Vecchia del Pinocchio, 22 – 60100 Ancona (AN), Italy.

Date of the last revision of the text.

September 26, 2018.

Information leaflet is APPROVED by Order of the Ministry of Health of Ukraine No. 636 dated 01.10.2015

Registration Certificate No. UA/3920/01/01
Our Supporters

Evangelos G. Kilipiris, MD, DMD from the National Institute of Children’s Diseases and Faculty of Medicine at Comenius University, Bratislava, Slovak Republic. A kind support of Dr. Kilipiris during the 5 years at the position of Director, Journal Development Department helped our journal to move forward and to evolve. An honorary plaque was presented to him on behalf of the Chief Editor with words “To a Founding Director, Author of Multiple Articles and Reviews, Great Thanks and Appreciation.” Photo was taken on November 23, 2021.
### Content

**A1** Publisher & Editorial Office Information  
**A2** Editorial Board  
**A5** Our Supporters  
**A6** Content, Courtesy, & Erratum

#### BUSINESS: EDITORIAL

**129** Region of Recent Hostilities: Disruption of Chain of Work Processes in the Practice of Oral Surgeon: Opportunity for the New Generation of Stomatologists  
Ivan V. Nagorniak

#### CASE

**131** Odontogenic Cutaneous Fistula and Abscess of the Superficial Peri-Zygomatic Area  
Ievgen I. Fesenko

---

**COURTESY**

*Journal’s cover image (virtual surgical planning for a segmental mandibular reconstruction with fibula transplant) is courtesy of Rui P. Fernandes, MD, DMD, FACS, FRCS.*

https://doi.org/10.23999/j.dtomp.2017.1.1
Region of Recent Hostilities: Disruption of Chain of Work Processes in the Practice of Oral Surgeon: Opportunity for the New Generation of Stomatologists

Ivan V. Nagorniak

Day 247 of a full-scale Russian invasion in Europe. The recent rocket attack on Kyiv during the morning commute and an attack by kamikaze drones is not something that can contribute to a positive work atmosphere and a boom in job interviews. Such continuous acts of terrorism can only cause a disruption in the chains of work processes. In stomatology, such chains cannot be built overnight. Typically, it takes years of collaboration and growth of the trust.

The quality of the relationship between the members of the chain, speed of collaboration, accessibility of stomatologist for the particular patient are vital for the success of the entire chain having a positive effect on profitability and existence of the whole (Huntley, 2006; Atrek et al, 2014; Nagorniak, 2022).

On other hand, such gaps in the chains of work processes are the chances for the young, less experienced stomatologists of all specialties—orthodontists, prosthetic stomatologists, surgeons focused on dental implants, etc. A chance to take the place of more experienced and famous stomatologists.

Summarizing the 247 days of Russia’s war of aggression against Ukraine, the following conclusions can be drawn regarding the disruption of work process chains in Kyiv city and options for their resolution:

- Percentage of female stomatologists and doctors from medical departments which evacuated are higher comparing to male colleagues. Maybe, upon the repair of the broken work chains for the period till victory over occupiers, oral surgeon should focus on male colleagues with reason to avoid possible future disruption of a repaired work chains.
- On other hand, we must avoid discrimination...

Please cite this article as: Nagorniak IV. Region of recent hostilities: disruption of chains of work processes in the practice of oral surgeon: opportunity for the new generation of stomatologists. J Diagn Treat Oral Maxillofac Pathol 2022;6(10): 129–30.

Available online 28 October 2022

https://doi.org/10.23999/j.dtomp.2022.10.1
© 2022 OMF Publishing LLC. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by-nc/4.0/).
based on gender.

• Young and/or less experienced stomatologist can receive their chance to start collaboration with highly experienced team or to hold a position in a clinic of their dream.

• Delay (loss of time) for the period of searching for new partners to resume the chain of work processes affects the ability to perform certain manipulations and, as a result, affects the profitability of the practice. Thus, the practice owner or practitioner should react promptly and dedicate part of their time and efforts to repair the chain as soon as possible. Moreover, those stomatological practice owners who will manage this challenge faster than others will be more successful.

• While trying to find the positive in this difficult wartime situation, we can say that such disruptions to work processes are also a way to refresh the stomatological team and find new talents.

REFERENCES (6)


CASE

Odontogenic Cutaneous Fistula and Abscess of the Superficial Peri-Zygomatic Area

Ievgen I. Fesenko

SUMMARY

Purulent processes of the zygomatic and peri-zygomatic area are not common. Among etiologies are: otitis media, complication of zygomatic implantation, osteomyelitis, medication-related osteonecrosis of the jaw, drug-related osteonecrosis, and odontogenic infection. This article highlights the first literature reported case of clinical presentation of odontogenic abscess and cutaneous fistula of the superficial peri-zygomatic area from the upper third molar. The preoperative and follow-up photographs of a 76-year-old Caucasian male patient are demonstrated. The uniqueness of this case is that until now the upper third molars never been published as a source of abscesses of the peri-zygomatic area.
INTRODUCTION

Purulent processes of the zygomatic and peri-zygomatic area are not common. Among etiologies are: otitis media,\(^1,2\) complication of zygomatic implants placement,\(^3,4\) osteomyelitis,\(^5\) medication-related osteonecrosis of the jaw (MRONJ), "Krokodil" drug-related osteonecrosis,\(^6\) and odontogenic infection\(^7,8\). The last one in the peri-zygomatic area can manifest in a form of sinus tract,\(^7\) abscess,\(^8\) and even phlegmon.\(^1\) To our literature search in English language there is no publication data which presents the clinical images of odontogenic cutaneous fistula and abscess of the peri-zygomatic area from upper third molar. That is why we are presenting the pre- and postoperative images of such rare case in a male patient.

CASE

A 76-year-old Caucasian male patient was referred to our hospital by doctor-stomatologist-surgeon from the stomatological polyclinic in Kyiv region. The patient appeared in the Center of Maxillofacial Surgery in 2016 at 10:18 p.m. with a significant swelling, erythema, and pyorrhea from cutaneous fistula in a right peri-zygomatic area (Figs 1A and 2A). According to patient complaints the pain appeared in the tooth 1.8 (upper right third molar) a week before, and then the swelling in a right peri-zygomatic area appeared and began to increase with gradual erythema of the skin above it. Tooth 1.8 was extracted by doctor in a Kyiv region on the day of the visit to the polyclinic (i.e., out-patient clinic). Mouth opening was free. Panoramic radiography (Planmeca ProMax® 2D S3, Planmeca, Helsinki, Finland) performed in Kyiv Regional Clinical Hospital showed the empty socket of the tooth 1.8 and no radiological evidence of tooth remains.

Under the intramuscular injection of Dexalgini Inject 50 mg/2.0 ml (Laboratorios Menarini S.A., Barcelona, Spain; A. Menarini Manufacturing Logistics and Services Srl, Prato, Italy), first, applying the halsted-mosquitoatraumatic hemostat (curved) the evacuation of the purulent content was performed. Then, finger revision of the purulent wound by a little finger was done. Purulent content in amount of ~6.0 ml was obtained. Irrigation of the wound with antiseptic solution was done and a sterile gauze bandage with Oflocain-Darnitsa® (Pharmaceutical Firm Darnitsa, PRJSC, Kyiv, Ukraine) was applied (inside the wound). There was no need to drain a purulent wound using tubular perforated drainage due to the evacuation of purulent contents through an expanded fistula.

General state and condition of the local tissues improved day by day. On a day 4 of the postoperative period, the wound healed by secondary intention (Figs 1B and 2B) and its condition was acceptable. The patient was discharged that day from the hospital with postoperative recommendations—Solcoseryl® ointment (MEDA Pharmaceuticals Switzerland GmbH, Dübendorf, Switzerland) for several days and carrying out dental prosthetics.

DISCUSSION

The term “zygomatic abscess” in English literature is commonly applied to the zygomatic root abscess—a rare extra cranial complication of acute otitis media.\(^1,2\) In the East European states (e.g., Ukraine), in oral and maxillofacial surgery publications, the term “zygomatic abscess/phlegmon” is applied to the purulent infection of superficial peri-zygomatic area.\(^8\) But only rare literature sources report odontogenic infection of such abscesses as the possible etiology.\(^8\) Reported odontogenic source is infection from the upper premolars or first molar.\(^8\)

Peri-zygomatic (i.e., peri-malar) area includes the soft tissues which surround the zygomatic bone outside the orbit. To be clear, it’s reasonable to distinct superficial and deep peri-zygomatic area. Mendelson et al (2012) describe in the superficial peri-zygomatic region location of the prezygomatic cellular space.\(^9\)

Odontogenic cutaneous sinus tract with skin fistula as one of its manifestations in the peri-zygomatic area have been reported, but the area was termed differently. Lee et al (2016) describe it as buccal cheek area.\(^7\) According to their data, in that area the odontogenic cutaneous sinus tract was manifested in 14.7 percent of odontogenic sinus tract cases (from upper first and second premolars [20 percent] and first and second molars [80 percent]).\(^7\)

Suppurated congenital cysts of the zygomatic area are also reported and should be taken into account for the differential diagnosis in similar manifestations.\(^8\)

Before this inflammatory process, the patient did not notice the presence of the skin fistula or swelling.
FIGURE 1. A, Preoperative view of a 76-year-old male patient with facial swelling in the right peri-zygomatic area. A notable purulent discharge from a skin fistula is labeled by arrow. B, Postoperative view on a day 4. The wound is healing by secondary intention.

FIGURE 2. Preoperative (A) and postoperative view on a day 4 (B).
in this area. This fact and the absence of firm intraoral submucosal strand upon palpation allowed us to rule out the diagnosis of the odontogenic cutaneous sinus tract manifested with cutaneous fistula (Baba et al, 2017) or abscess. But this purulent process could be considered as one of the stages of sinus tract formation if the tooth was preserved without endodontic treatment.

Such purulent condition in that area should be managed as soon as possible to avoid zygomatic bone osteomyelitis, further spread of the inflammatory process, and long-term impairment of social life due to cosmetic problems.

CONCLUSIONS

This paper highlights the first literature reported case of clinical presentation of odontogenic abscess and cutaneous fistula of the superficial peri-zygomatic area from the upper third molar. The preoperative and follow-up photographs are demonstrated. The uniqueness of this case is that until now the upper third molars never been published as a source of abscesses of the peri-zygomatic area.

FUNDINGS

No funding was received for this study.

PATIENT CONSENT

The patient provided written consent for the use of his image.

REFERENCES (10)


https://doi.org/10.4103/0975-5950.94478


https://doi.org/10.1016/j.ijporl.2004.10.018


https://doi.org/10.15644%2Fasc50%2F3%2F8


https://doi.org/10.1111/cor.13900


https://doi.org/10.1016/j.jcms.2019.11.002


https://doi.org/10.1097/00006534-200209010-00026


https://doi.org/10.1002/crr3.907
U-Impl®
SWITZERLAND

EN ISO 13485: 2012
CERTIFICATION
ISO 9001: 2015

No R3M 804 252 B2
Сертифікат відповідності технічного регламенту щодо медичних виробів

Switzerland Aarbergerstrasse 107A, CH-2502
Biel, Phone/Fax +41 323230188
info@u-impl.com
www.u-impl.com